Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen(Washington University in St. Louis), Xianwen Zhang(The University of Texas Medical Branch at Galveston), James Brett Case(Washington University in St. Louis), Emma S. Winkler(Washington University in St. Louis), Yang Liu(The University of Texas Medical Branch at Galveston), Laura A. VanBlargan(Washington University in St. Louis), Jianying Liu(The University of Texas Medical Branch at Galveston), John M. Errico(Washington University in St. Louis), Xuping Xie(The University of Texas Medical Branch at Galveston), Naveenchandra Suryadevara(Vanderbilt University Medical Center), Pavlo Gilchuk(Vanderbilt University Medical Center), Seth J. Zost(Vanderbilt University Medical Center), Stephen Tahan(Washington University in St. Louis), Lindsay Droit(Washington University in St. Louis), Jackson S. Turner(Washington University in St. Louis), Wooseob Kim(Washington University in St. Louis), Aaron J. Schmitz(Washington University in St. Louis), Mahima Thapa(Washington University in St. Louis), David Wang(Washington University in St. Louis), Adrianus C. M. Boon(Washington University in St. Louis), Rachel M. Presti(Washington University in St. Louis), Jane A. O’Halloran(Washington University in St. Louis), Alfred H.J. Kim(Washington University in St. Louis), Parakkal Deepak(Washington University in St. Louis), Dora Pinto(Vir Biotechnology (Switzerland)), Daved H. Fremont(Washington University in St. Louis), James E. Crowe(Vanderbilt University Medical Center), Davide Corti(Vir Biotechnology (Switzerland)), Herbert W. Virgin(Washington University in St. Louis), Ali H. Ellebedy(Saint Louis University), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Michael Diamond(Washington University in St. Louis)
Cited by 1,015Open Access